Chimeric antigen receptors (CARs)—also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen. The receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor. Wikipedia (CC BY-SA 3.0)
2023 Articles
1 244 articles
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells
- Andrew R Haas, Ryan J Golden, Leslie A Litzky, …, Steven M Albelda, Carl H June, Janos L Tanyi
- Mol Ther, 10.1016/j.ymthe.2023.06.006
Design of diversified chimeric antigen receptors through rational module recombination
- Wen Si, Ying-Ying Fan, Shi-Zhen Qiu, …, Wen Huang, Hao-Peng Wang, Ping Wei
- None, 10.1016/j.isci.2023.106529
Barnase-barstar Specific Interaction Regulates Car-T Cells Cytotoxic Activity toward Malignancy
- R S Kalinin, V O Shipunova, Y P Rubtsov, …, N V Gnuchev, A G Gabibov, S M Deyev
- Dokl Biochem Biophys, 10.1134/s1607672922700041
Engineering second-generation TCR-T cells by site-specific integration of TRAF-binding motifs into the CD247 locus
- Sangjoon Lah, Segi Kim, In Kang, …, Hyeon-Ki Jang, Sangsu Bae, Chan Hyuk Kim
- J Immunother Cancer, 10.1136/jitc-2022-005519
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR
- Evangelia Kokalaki, Biao Ma, Mathieu Ferrari, …, Shimobi Onuoha, Shaun Cordoba, Martin Pule
- Mol Ther, 10.1016/j.ymthe.2023.03.020
Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy
- Theo Lorenzini, Bruno L Cadilha, Hannah Obeck, …, Tobias Feuchtinger, Stefan Endres, Sebastian Kobold
- Br J Cancer, 10.1038/s41416-023-02332-9
CAR T-cell therapy: Reprogramming patient’s immune cell to treat cancer
- Anil Kumar Mavi, Sonal Gaur, Gauri Gaur, …, Babita, Neelesh Kumar, Umesh Kumar
- Cell Signal, 10.1016/j.cellsig.2023.110638
T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors
- Diana Rasoulouniriana, Nadine Santana-Magal, Amit Gutwillig, …, Meora Feinmesser, Peleg Rider, Yaron Carmi
- Cancer Immunol Res, 10.1158/2326-6066.cir-22-0423
Strategies for enhancing CAR T cell expansion and persistence in HIV infection
- Frederik Holm Rothemejer, Nanna Pi Lauritsen, Ole Schmeltz Søgaard, …, Nanna Pi Lauritsen, Ole Schmeltz Søgaard, Martin Tolstrup
- Front Immunol, 10.3389/fimmu.2023.1253395
Universal chimeric Fcγ receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy
- Wen Zhu, Yang Wang, Liangyin Lv, …, Mingzhe Zhou, Jianwei Zhu, Huili Lu
- None, 10.1016/j.apsb.2023.02.004
2022 Articles
112 articles
Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19+ malignancy
- Heather Campbell, Meghan D Storlie, Sara Bolivar-Wagers, …, Sophie Viaud, Travis S Young, Bruce R Blazar
- J Immunother Cancer, 10.1136/jitc-2022-005934
Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes
- Anze Smole, Anze Smole, Anze Smole, Anze Smole, Anze Smole, Anze Smole
- Radiol Oncol, 10.2478/raon-2022-0049
Expression of inducible factors reprograms CAR-T cells for enhanced function and safety
- Anže Smole, Alexander Benton, Mathilde A Poussin, …, Beatriz M Carreno, Monica Casucci, Daniel J Powell
- Cancer Cell, 10.1016/j.ccell.2022.11.006
Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours
- Yuto Watanabe, Kenji Murata, Shuto Hamada, …, Munehide Nakatsugawa, Toshihiko Yamashita, Toshihiko Torigoe
- Br J Cancer, 10.1038/s41416-022-02100-1
Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
- Konstantinos Drougkas, Konstantinos Karampinos, Ioannis Karavolias, …, Efthymios Triantafyllou, Ioannis Trontzas, Elias Kotteas
- J Cancer Res Clin Oncol, 10.1007/s00432-022-04547-4
Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells
- Tatsuki Ueda, Sara Shiina, Shoichi Iriguchi, …, Tetsuya Nakatsura, Koji Tamada, Shin Kaneko
- Nat Biomed Eng, 10.1038/s41551-022-00969-0
Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection
- Wuling Li, Xiuxiu Zhu, Yanmin Xu, …, Guixue Wang, Junjie Shen, Cheng Qian
- Front Immunol, 10.3389/fimmu.2022.1052717
[CAR-T cells development in solid tumors]
- Nathan El Ghazzi, Antoine Italiano, Jacques-Olivier Bay, …, Antoine Italiano, Jacques-Olivier Bay, Aurore Dougé
- Bull Cancer, 10.1016/j.bulcan.2022.12.001
Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells
- Brianna C Davey, Mary S Pampusch, Emily K Cartwright, …, Aaron Rendahl, Edward A Berger, Pamela J Skinner
- Front Immunol, 10.3389/fimmu.2022.1032537
Role of antibody engineering in generation of derivatives starting from MOv19 MAb: 40 years of biological/therapeutic tools against folate receptor alfa
- Barbara Frigerio, Matilde Montermini, Canevari Silvana, …, Matilde Montermini, Canevari Silvana, Mariangela Figini
- None, 10.1093/abt/tbac026